Fig. 1

Molecular summary of HRD screening and clinical journey of the five HRD uLMS identified. A Summary of results from screening 58 uLMS samples via either whole genome sequencing (WGS), whole exome sequencing (WES), TruSight Oncology 500 (TSO500) panel testing or BRCA1/2 panel sequencing. Genome doubling (GD), percentage loss of heterozygosity (LOH) and results of MS-HRM methylation analysis of BRCA1 and RAD51C promoters (denoted as BRCA1(me) and RAD51C(me), respectively) also shown. HRDetect scores and CHORD percentage readouts from UoM pipeline are as shown. Blanks indicate test was not run (for BRCA1(me) and RAD51C(me)), the tumour purity was not high enough to provide accurate scores or that the type of analysis used cannot report on the parameter. uLMS numbers refer to specific uLMS cases described in the text. B Timeline of uLMS patients who, based on HRD screening, received PARPi (olaparib) ± platinum therapy as part of their treatment history. Time of sample collection, type of molecular test, time of molecular reporting, and commencement of PARPi therapy are shown along with other types of therapy received and tumour responses where available